NEUPRO 2 mg/24 h, medicated transdermal patch 7 patches in individual sachets
Active ingredients: (6S)-rotigotine
Commercialized according to BDPMDispensing in France: Prescription only
Medicated transdermal patch7 patches in individual sachetstransdermique
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- NEUPRO 2 mg/24 h, dispositif transdermique
- Pharmaceutical form
- dispositif
- Route of administration
- transdermique
- Presentation description
- 7 sachet(s)-dose(s) copolymère d'éthylène aluminium polyéthylène basse densité (PEBD) papier polyéthylène de 1 dispositif(s)
- Marketing authorisation holder
- UCB PHARMA BELGIQUE
- Reimbursement according to BDPM
- 65%
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans le cas suivant :<br><br>- Maladie de Parkinson :<br><br>. traitement des symptômes cliniques précoces de la maladie, sans association à la lévodopa<br>. traitement des symptômes cliniques avancés de la maladie, en association avec la lévodopa ; JOURNAL OFFICIEL ; 04/08/10
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 18 Feb 2011
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69741731CIP73732850CIP133400937328500Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ROTIGOTINEdispositif | 4,5 mg · un dispositif | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.